Ergomed (ERGO LN)

Analysis

Health Care • United Kingdom

Ergomed provides specialized services to the pharmaceutical and biotechnology industries, focusing on clinical development, trial management, and pharmacovigilance. The company operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV), offering solutions for all phases of clinical trials and post-approval drug safety. Ergomed was founded in 1997 and is headquartered in Guildford, United Kingdom.

Refresh

Exchange Announcement • 10 Nov 2023 23:47

Holding(s) in Company

Exchange Announcement • 10 Nov 2023 23:05

Holding(s) in Company

Exchange Announcement • 09 Nov 2023 22:27

Issue of Equity and Rule 2.9 Announcement

Exchange Announcement • 01 Nov 2023 15:00

Issue of Equity and Rule 2.9 Announcement

Exchange Announcement • 27 Oct 2023 13:00

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Holding(s) in Company

Holding(s) in Company

Issue of Equity and Rule 2.9 Announcement

Issue of Equity and Rule 2.9 Announcement

Satisfaction of Conditions